IP Library Granted Patent US 10,982,201
Granted Patent B2
US 10,982,201 · App. 16/357,191 · Granted Apr 20, 2021

Treatment of gluten intolerance and related conditions

Inventors: David C. Schriemer (Chestermere, CA); Petr Man (Prague, CZ); Hynek Mrazek (Prague, CZ); Martial Rey (Calgary, CA)
Assignee: Codexis, Inc.
C12N9/63A23L29/06A23L33/10A23L33/105A61K38/488C12Y304/23012A23V2002/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,982,201
App. No.
16/357,191
Granted
Apr 20, 2021
Kind
B2
Abstract

Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease. Further provided herein are pharmaceutical compositions comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof to treat bacterial infections of the gastrointestinal tract, such as C. difficile or H. pylori . Further provided herein are compositions comprising recombinant nepenthesin I or nepenthesin II, or homologous proteins, and methods for making the same.

Claims (24)

1. A composition for treating or attenuating gluten intolerance comprising:

(a) an effective amount of nepenthesin, the nepenthesin comprising an amino acid sequence that is at least 85% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, without a plant signal sequence and having aspartic protease activity; and

(b) an effective amount of a buffer to maintain the pH of said composition at a pH of 5 or above, wherein said nepenthesin is inactive prior to administration;

wherein said effective amount of nepenthesin is sufficient to degrade gluten upon oral administration of said solid composition to a patient suffering from gluten intolerance.

2. The composition of claim 1 , wherein said effective amount of nepenthesin is between about 1 mg and about 1 g, wherein about refers to a variation of up to ±5%.

3. The composition of claim 1 , further comprising at least one additional agent selected from the group consisting of an inhibitor of a transglutaminase, an anti-inflammatory agent, a COX-2 inhibitor, a p38 MAP kinase inhibitor, a mast cell-stabilizing agent, an anti-ulcer agent, an anti-allergy agent, and an anti-TNF-α agent.

4. The composition of claim 1 , further comprising at least one additional enzyme selected from the group consisting of a gastric protease, an aspartic protease, and a prolyl endopeptidase.

5. The composition of claim 1 , wherein said composition is formulated to release said nepenthesin in a patient's stomach.

6. The composition of claim 2 , wherein said effective amount of said nepenthesin is between about 1 mg and about 500 mg.

7. The composition of claim 2 , wherein said effective amount of said nepenthesin is between about 1 mg and about 200 mg.

8. The composition of claim 1 , wherein the gluten intolerance is celiac disease, wheat allergy, gluten sensitivity, or dermatitis herpetiformis.

9. The composition of claim 1 , wherein the nepenthesin comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 3.

10. The composition of claim 1 , wherein the nepenthesin comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 4.

11. The composition of claim 1 , wherein the nepenthesin comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 5.

12. The composition of claim 1 , wherein the nepenthesin comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of set forth in SEQ ID NO: 6.

13. The composition of claim 1 , wherein the nepenthesin comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 7.

14. The composition of claim 1 , wherein the nepenthesin comprises an amino acid sequence that is at least 90% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

15. The composition of claim 1 , wherein the nepenthesin comprises an amino acid sequence that is at least 95% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

16. The composition of claim 1 , wherein the nepenthesin is recombinant nepenthesin.

17. The composition of claim 1 , wherein the nepenthesin comprises the amino acid sequence set forth in SEQ ID NO: 3.

18. The composition of claim 1 , wherein the nepenthesin comprises the amino acid sequence set forth in SEQ ID NO: 4.

19. The composition of claim 1 , wherein the nepenthesin comprises the amino acid sequence set forth in SEQ ID NO: 5.

20. The composition of claim 1 , wherein the nepenthesin comprises the amino acid sequence of set forth in SEQ ID NO: 6.

21. The composition of claim 1 , wherein the nepenthesin comprises the amino acid sequence set forth in SEQ ID NO: 7.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 8, 2025
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
To: CODEXIS, INC.
Reel/Frame 069789/0740 →
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2020
From: NEPETX, LLC
To: CODEXIS, INC.
Reel/Frame 052804/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2019
From: SCHRIEMER, DAVID C.; REY, MARTIAL; MAN, PETR; MRAZEK, HYNEK
To: NEPETX, LLC
Reel/Frame 048634/0380 →
Continuity (6)
Continuation 15209681 · Jul 13, 2016
Continuation 14620066 · Feb 11, 2015
Division 13843369 · Mar 15, 2013
Provisional Application 61797040 · Nov 27, 2012
Provisional Application 61729210 · Nov 21, 2012
Related Publication 20200040322A1 · Feb 6, 2020